A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis · Progressive Pulmonary Fibrosis · Pulmonary Fibrosis Secondary to Systemic Sclerosis · Pulmonary Fibrosis, Interstitial Lung Disease · Interstitial Lung Disease · Interstitial Lung Disease Due to Connective Tissue Disease (Disorder) · Interstitial Lung Disease in Patients With Rheumatoid Arthritis · Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere · Hypersensitivity Pneumonitis · Interstitial Lung Disease With Systemic Sclerosis
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 398 (final count)
- Started
- Apr 3, 2024
- Main results expected
- Jun 2027
- Fully finished
- Jun 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To evaluate the effect of AP01 high dose twice a day (BID) or AP01 low dose twice a day (BID) compared to placebo twice a day (BID)
Measured over: Week 52
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06329401 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC